Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repisalud
Publicación Artículo científico (JournalArticle)

Impact of environmental neurotoxic: current methods and usefulness of human stem cells

  • Rosca, Andreea
  • Coronel Lopez, Raquel
  • Moreno, Miryam
  • Gonzalez-Martin-Niño, Rosa Maria
  • Oniga, Andreea
  • Martin, Alberto
  • López-Alonso, Victoria
  • González-Caballero, MCarmen
  • Liste-Noya, Isabel
The development of central nervous system is a highly coordinated and complex process. Any alteration of this process can lead to disturbances in the structure and function of the brain, which can cause deficits in neurological development, resulting in neurodevelopmental disorders, including, for example, autism or attention-deficit hyperactivity disorder. Exposure to certain chemicals during the fetal period and childhood is known to cause developmental neurotoxicity and has serious consequences that persist into adult life. For regulatory purposes, determination of the potential for developmental neurotoxicity is performed according the OECD Guideline 426, in which the test substance is administered to animals during gestation and lactation. However, these animal models are expensive, long-time consuming and may not reflect the physiology in humans; that makes it an unsustainable model to test the large amount of existing chemical products, hence alternative models to the use of animals are needed. One of the most promising methods is based on the use of stem cell technology. Stem cells are undifferentiated cells with the ability to self-renew and differentiate into more specialized cell types. Because of these properties, these cells have gained increased attention as possible therapeutic agents or as disease models. Here, we provide an overview of the current models both animal and cellular, available to study developmental neurotoxicity and review in more detail the usefulness of human stem cells, their properties and how they are becoming an alternative to evaluate and study the mechanisms of action of different environmental toxicants.
Repisalud
Publicación Artículo científico (JournalArticle)

Physiological and pathological effects of amyloid-β species in neural stem cell biology

  • Bernabeu-Zornoza, Adela
  • Coronel Lopez, Raquel
  • Palmer, Charlotte
  • Monteagudo, Maria
  • Zambrano, Alberto
  • Liste-Noya, Isabel
Although amyloid-β peptide is considered neurotoxic, it may mediate several physiological processes during embryonic development and in the adult brain. The pathological function of amyloid-β peptide has been extensively studied due to its implication in Alzheimer's disease, but its physiological function remains poorly understood. Amyloid-β peptide can be detected in non-aggregated (monomeric) and aggregated (oligomeric and fibrillary) forms. Each form has different cytotoxic and/or physiological properties, so amyloid-β peptide and its role in Alzheimer's disease need to be studied further. Neural stem cells and neural precursor cells are good tools for the study on neurodegenerative diseases and can provide future therapeutic applications in diseases such as Alzheimer's disease. In this review, we provide an outline of the effects of amyloid-β peptide, in monomeric and aggregated forms, on the biology of neural stem cells/neural precursor cells, and discuss the controversies. We also describe the possible molecular targets that could be implicated in these effects, especially GSK3β. A better understanding of amyloid-β peptide (both physiological and pathological), and the signaling pathways involved are essential to advance the field of Alzheimer's disease.
Repisalud
Publicación Artículo científico (JournalArticle)

Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma

  • Gonzalez-Gomez, Pilar
  • Crecente-Campo, Jose
  • Zahonero, Cristina
  • Fuente, Maria de la
  • Hernández-Laín, Aurelio
  • Mira, Helena
  • Sánchez-Gómez, Pilar
  • Garcia-Fuentes, Marcos
Glioblastoma tumor initiating cells are believed to be the main drivers behind tumor recurrence, and therefore therapies that specifically manage this population are of great medical interest. In a previous work, we synthesized controlled release microspheres optimized for intracranial delivery of BMP7, and showed that these devices are able to stop the in vitro growth of a glioma cell line. Towards the translational development of this technology, we now explore these microspheres in further detail and characterize the mechanism of action and the in vivo therapeutic potential using tumor models relevant for the clinical setting: human primary glioblastoma cell lines. Our results show that BMP7 can stop the proliferation and block the self-renewal capacity of those primary cell lines that express the receptor BMPR1B. BMP7 was encapsulated in poly (lactic-co-glycolic acid) microspheres in the form of a complex with heparin and Tetronic, and the formulation provided effective release for several weeks, a process controlled by carrier degradation. Data from xenografts confirmed reduced and delayed tumor formation for animals treated with BMP7-loaded microspheres. This effect was coincident with the activation of the canonical BMP signaling pathway. Importantly, tumors treated with BMP7-loaded microspheres also showed downregulation of several markers that may be related to a malignant stem cell-like phenotype: CD133(+), Olig2, and GFAPδ. We also observed that tumors treated with BMP7-loaded microspheres showed enhanced expression of cell cycle inhibitors and reduced expression of the proliferation marker PCNA. In summary, BMP7-loaded controlled release microspheres are able to inhibit GBM growth and reduce malignancy markers. We envisage that this kind of selective therapy for tumor initiating cells could have a synergistic effect in combination with conventional cytoreductive therapy (chemo-, radiotherapy) or with immunotherapy.
Repisalud
Publicación Artículo científico (JournalArticle)

Physiological effects of amyloid precursor protein and its derivatives on neural stem cell biology and signaling pathways involved

  • Coronel Lopez, Raquel
  • Palmer, Charlotte
  • Bernabeu-Zornoza, Adela
  • Monteagudo, Maria
  • Rosca, Andreea
  • Zambrano, Alberto
  • Liste-Noya, Isabel
The pathological implication of amyloid precursor protein (APP) in Alzheimer's disease has been widely documented due to its involvement in the generation of amyloid-β peptide. However, the physiological functions of APP are still poorly understood. APP is considered a multimodal protein due to its role in a wide variety of processes, both in the embryo and in the adult brain. Specifically, APP seems to play a key role in the proliferation, differentiation and maturation of neural stem cells. In addition, APP can be processed through two canonical processing pathways, generating different functionally active fragments: soluble APP-α, soluble APP-β, amyloid-β peptide and the APP intracellular C-terminal domain. These fragments also appear to modulate various functions in neural stem cells, including the processes of proliferation, neurogenesis, gliogenesis or cell death. However, the molecular mechanisms involved in these effects are still unclear. In this review, we summarize the physiological functions of APP and its main proteolytic derivatives in neural stem cells, as well as the possible signaling pathways that could be implicated in these effects. The knowledge of these functions and signaling pathways involved in the onset or during the development of Alzheimer's disease is essential to advance the understanding of the pathogenesis of Alzheimer's disease, and in the search for potential therapeutic targets.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tbr1 Misexpression Alters Neuronal Development in the Cerebral Cortex

  • Crespo, Inmaculada
  • Pignatelli Garrigos, Jaime
  • Kinare, Veena
  • Esgleas, Miriam
  • Roman, María José
  • Canals, Josep María
  • Tole, Shubha
  • Vicario-Abejón, Carlos
Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature. This work was funded by grants from the Spanish “Ministerio de Economía y Competitividad and Ministerio de Ciencia, Innovación y Universidades” (MINECO and MICIU: SAF2013-4759R and SAF2016-80419-R to C.V.; RTI2018-099001-B-I00 to J.M.C), CIBERNED (CB06/05/0065 to C.V.), RETICS-Red de Terapia Celular (RD16/0011/0012 to J.M.C.), the "Comunidad de Madrid” (S2011/BMD-2336), and the CSIC Intramural program (Ref. 201320E054 to C.V.), the Generalitat de Catalunya (2017SGR-1408 to J.M.C.), and by a University Grants Commission fellowship to V.K. and Department of Atomic Energy, Government of India Project (RTI4003 to S.T.).